Shukui Qin

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 986 citations

Placebo Monotherapy, Health Sciences, Gastrointestinal Oncology +15

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2020 · 813 citations · Full text

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification

Jun Guo, Lu Si, Yan Kong et al. · Journal of Clinical Oncology · 2011 · 673 citations · Full text